Shui‐on Leung

556 total citations
28 papers, 472 citations indexed

About

Shui‐on Leung is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Shui‐on Leung has authored 28 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Radiology, Nuclear Medicine and Imaging, 15 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Shui‐on Leung's work include Monoclonal and Polyclonal Antibodies Research (22 papers), Glycosylation and Glycoproteins Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Shui‐on Leung is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (22 papers), Glycosylation and Glycoproteins Research (8 papers) and Radiopharmaceutical Chemistry and Applications (5 papers). Shui‐on Leung collaborates with scholars based in United States, China and Hong Kong. Shui‐on Leung's co-authors include Jerry Shevitz, David M. Goldenberg, Lisa B. Shih, Hans J. Hansen, Arnold S. Dion, H. J. Hansen, J. C. Murphy, Richard P. Junghans, Emma Whitelaw and Nicholas Proudfoot and has published in prestigious journals such as Nature, Nucleic Acids Research and PLoS ONE.

In The Last Decade

Shui‐on Leung

28 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shui‐on Leung United States 10 307 168 164 131 124 28 472
E. Seccamani Italy 5 321 1.0× 96 0.6× 152 0.9× 70 0.5× 45 0.4× 9 449
Sandra V. Dixon United Kingdom 5 378 1.2× 221 1.3× 162 1.0× 394 3.0× 145 1.2× 5 672
Robert Oldham United Kingdom 10 223 0.7× 151 0.9× 148 0.9× 198 1.5× 26 0.2× 15 423
Heidi H. van Ojik Netherlands 9 325 1.1× 263 1.6× 245 1.5× 322 2.5× 23 0.2× 11 620
G Wong United States 8 82 0.3× 163 1.0× 106 0.6× 97 0.7× 182 1.5× 10 391
Robyn Clark United States 6 258 0.8× 284 1.7× 121 0.7× 177 1.4× 26 0.2× 9 408
Stefania Martignone Italy 10 184 0.6× 224 1.3× 213 1.3× 107 0.8× 25 0.2× 17 479
GT Stevenson United Kingdom 8 193 0.6× 83 0.5× 101 0.6× 198 1.5× 40 0.3× 10 336
H.W. Willems Netherlands 10 246 0.8× 89 0.5× 201 1.2× 245 1.9× 25 0.2× 13 488
Ian R. Hardy United States 7 63 0.2× 423 2.5× 185 1.1× 161 1.2× 59 0.5× 10 556

Countries citing papers authored by Shui‐on Leung

Since Specialization
Citations

This map shows the geographic impact of Shui‐on Leung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shui‐on Leung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shui‐on Leung more than expected).

Fields of papers citing papers by Shui‐on Leung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shui‐on Leung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shui‐on Leung. The network helps show where Shui‐on Leung may publish in the future.

Co-authorship network of co-authors of Shui‐on Leung

This figure shows the co-authorship network connecting the top 25 collaborators of Shui‐on Leung. A scholar is included among the top collaborators of Shui‐on Leung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shui‐on Leung. Shui‐on Leung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhu, Leilei, Rong Shi, Yujie Ye, et al.. (2023). A randomized, controlled single, and multiple ascending dose trial of the safety, pharmacokinetics and pharmacodynamics of SN1011 in healthy subjects. Clinical and Translational Science. 16(10). 1982–1996. 1 indexed citations
3.
Li, Jing, Mengtao Li, Di Wu, et al.. (2021). SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study. Lara D. Veeken. 61(5). 1841–1848. 7 indexed citations
4.
Zhao, Qian, Xia Chen, Jiang Ji, et al.. (2021). An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis. International Journal of Clinical Pharmacology and Therapeutics. 59(11). 691–704. 2 indexed citations
5.
6.
7.
Leung, Shui‐on, Zhengxing Qu, H. J. Hansen, et al.. (1999). The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments.. PubMed. 5(10 Suppl). 3106s–3117s. 3 indexed citations
8.
Qu, Zhengxing, et al.. (1999). Humanization of Immu31, an alpha-fetoprotein-specific antibody.. PubMed. 5(10 Suppl). 3095s–3100s. 4 indexed citations
9.
Losman, Michele J., Zhengxing Qu, Indira Krishnan, et al.. (1999). Generation and monitoring of cell lines producing humanized antibodies.. PubMed. 5(10 Suppl). 3101s–3105s. 5 indexed citations
10.
Nolan, Kathleen F., Yun Cheng, Yoshiko Akamatsu, et al.. (1999). Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.. PubMed. 5(12). 3928–41. 75 indexed citations
11.
Qu, Zhengxing, Robert M. Sharkey, Hans J. Hansen, et al.. (1998). Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates. Journal of Immunological Methods. 213(2). 131–144. 16 indexed citations
12.
Losman, Michele J., Hans J. Hansen, Indira Krishnan, et al.. (1997). Generation of a high-producing clone of a humanized anti-B-cell lymphoma monoclonal antibody (hLL2). Cancer. 80(S12). 2660–2666. 16 indexed citations
13.
Leung, Shui‐on, David M. Goldenberg, Arnold S. Dion, et al.. (1995). Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. Molecular Immunology. 32(17-18). 1413–1427. 91 indexed citations
14.
15.
Govindan, Serengulam V., D M Goldenberg, Gary L. Griffiths, et al.. (1995). Site-specific modifications of light chain glycosylated antilymphoma (LL2) and anti-carcinoembryonic antigen (hImmu-14-N) antibody divalent f1agments.. PubMed. 55(23 Suppl). 5721s–5725s. 4 indexed citations
16.
Leung, Shui‐on, Jerry Shevitz, Arnold S. Dion, et al.. (1994). Chimerization of LL2, a Rapidly Internalizing Antibody Specific for B Cell Lymphoma. Hybridoma. 13(6). 469–476. 26 indexed citations
17.
Losman, Michele J., Shui‐on Leung, Jerry Shevitz, et al.. (1994). DEVELOPMENT AND EVALUATION OF THE SPECIFICITY OF A RAT MONOCLONAL ANTI-IDIOTYPE ANTIBODY, WN, TO AN ANTI-B-CELL LYMPHOMA MONOCLONAL ANTIBODY, mLL2. Journal of Immunotherapy. 16(2). 171–171. 1 indexed citations
18.
Sharkey, Robert M., Malik E. Juweid, Jerry Shevitz, et al.. (1994). PRECLINICAL AND CLINICAL EVALUATION OF A CDR-GRAFTED (HUMANIZED) ANTI-CARCINOEMBRYONIC ANTIGEN (CEA) MONOCLONAL ANTIBODY (MAb). Journal of Immunotherapy. 16(2). 164–164. 1 indexed citations
19.
Leung, Shui‐on, Emma Whitelaw, & Nicholas Proudfoot. (1989). Transcriptional and translational analysis of the human θ globin gene. Nucleic Acids Research. 17(20). 8283–8300. 10 indexed citations
20.
Leung, Shui‐on, Nicholas Proudfoot, & Emma Whitelaw. (1987). The gene for θ-globin is transcribed in human fetal erythroid tissues. Nature. 329(6139). 551–554. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Seccamani Breakdown of academic impact, for papers by Sandra V. Dixon Breakdown of academic impact, for papers by Robert Oldham Breakdown of academic impact, for papers by Heidi H. van Ojik Breakdown of academic impact, for papers by G Wong Breakdown of academic impact, for papers by Robyn Clark Breakdown of academic impact, for papers by Stefania Martignone Breakdown of academic impact, for papers by GT Stevenson Breakdown of academic impact, for papers by H.W. Willems Breakdown of academic impact, for papers by Ian R. Hardy
Rankless by CCL
2026